A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

Inclusion Criteria:

- The participant was treated with at least one dose of oritavancin for a suspected or
confirmed gram positive infection, as monotherapy or part of a broader regimen.

- At least 60 days has elapsed since the participant received the last dose of
oritavancin therapy (prior to data entry into the electronic Case Report Form).

Exclusion Criteria:

- The participant received oritavancin as a part of a controlled clinical trial.

- The participant received oritavancin as a part of a Medicines Company-sponsored single
or multi-centered pharmacoeconomic outcomes study.